You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 36 No. 12, November 1979 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Serum Calcium and Magnesium Levels in Schizophrenia

II. Possible Relationship to Extrapyramidal Symptoms

Paul E. Alexander, MD; Daniel P. van Kammen, MD; William E. Bunney, Jr, MD

Arch Gen Psychiatry. 1979;36(12):1372-1377.


Abstract

• The relationship between serum calcium and magnesium levels and neuroleptic-induced extrapyramidal symptoms (EPS) was studied in schizophrenic patients. The 16 patients in whom EPS developed had a significantly lower mean drug-free calcium level than the six patients in whom EPS did not develop. In patients in whom EPS developed, drug-free serum calcium and magnesium levels together correlated significantly with the neuroleptic dosage at which EPS first developed; lower calcium and magnesium values predicted EPS at lower dosages. We have previously shown that bom serum calcium and magnesium levels were significantly lower during neuroleptic treatment than in the drug-free state. In this study, a similar trend was observed, but the calcium value tended to be, and the magnesium value was significantly lower at the onset of neuroleptic-induced EPS than during the mean of an entire pimozide trial.



Author Affiliations

From the Section of Psychiatry and Human Behavior, Division of Biology and Medicine, Brown University; and the Intensive Treatment Unit, Butler Hospital, Providence, RI (Dr Alexander); and the Unit on Neuropsychopharmacology (Dr van Kammen), Biological Psychiatry Branch (Dr Bunney), National Institute of Mental Health, Bethesda, Md.


Footnotes

Accepted for publication Nov 13, 1978.

Read in part before the Sixth World Congress of Psychiatry, Honolulu, Aug 29, 1977.

Reprint requests to Butler Hospital 345 Blackstone Blvd, Providence, RI 02906 (Dr Alexander).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Psychiatry
Freedman
JAMA 1980;243:2208-2210.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1979 American Medical Association. All Rights Reserved.